Get the Stockscreener App
1.55
2.65%
0.04
Pre-market:
1.57
0.02
+1.29%
Akebia Therapeutics Inc stock is traded at $1.55, with a volume of 4.49M.
It is up +2.65% in the last 24 hours and up +1.97% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$1.51
Open:
$1.53
24h Volume:
4.49M
Relative Volume:
1.23
Market Cap:
$411.32M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-5.5357
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
+13.14%
1M Performance:
+1.97%
6M Performance:
-53.73%
1Y Performance:
-26.19%
1-Day Range:
$1.45
$1.56
1-Week Range:
$1.33
$1.56
52-Week Range:
$1.30
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.55 | 400.70M | 194.75M | -51.26M | -23.38M | -0.28 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | H.C. Wainwright | Buy |
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Loss Report: Can Akebia Therapeutics Inc weather a recessionAnalyst Downgrade & Entry Point Confirmation Alerts - baoquankhu1.vn
Winners Losers: Should I hold or sell Victorias Secret Co now2025 Breakouts & Breakdowns & High Conviction Buy Zone Picks - baoquankhu1.vn
Why The Narrative Around Akebia Therapeutics (AKBA) Is Shifting After New Valuation Reset - Yahoo Finance
Breaking Down Akebia Therapeutics: 4 Analysts Share Their Views - Benzinga
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $4.00 at Piper Sandler - MarketBeat
Piper Sandler Lowers Akebia Therapeutics (AKBA) Price Target to $4.00 | AKBA Stock News - GuruFocus
Akebia Therapeutics (NASDAQ:AKBA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Analyst Reiterates Buy Rating on Akebia Therapeutics (AKBA) with $6 PT | AKBA Stock News - GuruFocus
Akebia Therapeutics (NASDAQ:AKBA) CAO Sells $68,838.36 in Stock - MarketBeat
Akebia Therapeutics to present at Guggenheim Biotech Summit - Traders Union
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Surprises Report: Is Akebia Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Akebia Therapeutics reports inducement grants under Nasdaq listing rule - marketscreener.com
Trading Recap: Will IVCPW benefit from AI trendsWeekly Investment Recap & Accurate Entry/Exit Alerts - baoquankhu1.vn
Earnings Beat: Is Akebia Therapeutics Inc stock showing strong momentumWeekly Market Report & Weekly Return Optimization Alerts - baoquankhu1.vn
Akebia Therapeutics (AKBA): A Potential 272% Upside In The Healthcare Sector - DirectorsTalk Interviews
Akebia Therapeutics signs new headquarters lease and amends executive severance agreements - Investing.com Canada
Akebia Therapeutics announces corporate updates and 2026 pipeline outlook - MSN
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Aug Catalysts: Can Akebia Therapeutics Inc weather a recessionInflation Watch & Reliable Intraday Trade Alerts - baoquankhu1.vn
Income Plays: Whats the beta of Akebia Therapeutics Inc stockQuarterly Trade Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: A 275% Potential Upside That Investors Can't Ignore - DirectorsTalk Interviews
Highs Report: Can Akebia Therapeutics Inc deliver alpha2025 Support & Resistance & AI Enhanced Execution Alerts - baoquankhu1.vn
In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forced to take severe actions - simplywall.st
Exit Recap: Can Akebia Therapeutics Inc benefit from deglobalizationJuly 2025 Action & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Analyst Calls: What’s the beta of Akebia Therapeutics Inc. stock2025 Retail Activity & Daily Volume Surge Signals - baoquankhu1.vn
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA) - Seeking Alpha
Akebia reports first patient dosed in rare kidney disease trial By Investing.com - Investing.com Nigeria
Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
Akebia (AKBA) Updates on Vafseo and Rare Kidney Disease Pipeline - GuruFocus
Akebia Therapeutics (AKBA) Reports Growth in Vafseo Prescriptions - GuruFocus
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline - TipRanks
Akebia reports first patient dosed in rare kidney disease trial - Investing.com
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook - The Manila Times
Drugmaker maps next steps in Vafseo use and rare kidney disease trials - Stock Titan
How Akebia Therapeutics Inc. stock performs in weak economyJuly 2025 Closing Moves & AI Powered Buy and Sell Recommendations - Улправда
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Unveiling a Potential 262% Upside for Healthcare Investors - DirectorsTalk Interviews
What insider trading reveals about Akebia Therapeutics Inc. stockModel Comparison & HOKA buying tips before checkout - Улправда
How supply chain issues affect Akebia Therapeutics Inc. stock2025 Analyst Calls & Weekly Top Performers Watchlists - Улправда
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Is Akebia Therapeutics Inc. stock affected by interest rate hikesMarket Sentiment Summary & Stock Timing and Entry Methods - ulpravda.ru
How Akebia Therapeutics Inc. (AX9) stock trades pre earningsCPI Data & Trade Opportunity Analysis Reports - Улправда
Can Akebia Therapeutics Inc. stock outperform in 2025 bull market2025 Year in Review & Long-Term Safe Return Strategies - Улправда
Akebia announces first patient dosed in Phase 2 trial of praliciguat - Yahoo Finance
Akebia Therapeutics begins phase 2 trial for rare kidney disease drug - Investing.com Nigeria
Key facts: Akebia starts Phase 2 trial for Praliciguat; grants stock options - TradingView — Track All Markets
Akebia Therapeutics announces first patient dosed in phase 2 clinical trial of praliciguat - marketscreener.com
Akebia Therapeutics begins phase 2 trial for rare kidney disease drug By Investing.com - Investing.com South Africa
Akebia Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):